Heiner Wedemeyer, MD, PhD

Clinic for Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
Hannover, Niedersachsen, Germany

Disclosure(s): Abbott: Advisor/Consultant, Honoraria; AbbVie: Advisor/Consultant, Honoraria; Arbutus: Advisor/Consultant; Boeringer Ingelheim: Advisor/Consultant, Honoraria; Bristol Myers Squibb: Advisor/Consultant, Honoraria; Dicerna: Advisor/Consultant; Gilead Sciences, Inc.: Advisor/Consultant, Honoraria; Johnson & Johnson/Janssen-Cilag: Advisor/Consultant, Honoraria; Merck/Schering-Plough: Advisor/Consultant, Honoraria; MYR GmbH: Advisor/Consultant, Honoraria; Novartis: Advisor/Consultant, Honoraria; Roche: Advisor/Consultant, Honoraria; Siemens: Advisor/Consultant, Honoraria; Transgene: Advisor/Consultant, Honoraria; Viiv Healthcare: Advisor/Consultant, Honoraria; Vir Biotechnology: Advisor/Consultant

Presentation(s):

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT